ARCTIC - Operational Feasibility of Appropriate Plasmodium vivax Radical Cure with Tafenoquine or Primaquine After Quantitative G6PD Testing in Thailand

This is a phase IV, observational study. The Principal Investigator is Dr. Chantana Padungtod, M.D., DrPH (Director, Division of Vector Borne Diseases (DVBD)).  

Primary Objective:

  1. to investigate whether P. vivax patients ≥16 years old are treated with tafenoquine (TQ) in accordance with the appropriate level of G6PD enzyme activity.

Secondary Objectives:

  1. to investigate whether P. vivax patients ≥16 years are treated with daily primaquine (PQ) in accordance with the appropriate level of G6PD enzyme activity;
  2. to assess the correct application of the radical cure treatment algorithm for P. vivax patients receiving TQ or PQ;
  3. to measure the frequency of reported drug-induced Acute Haemolytic Anaemia (AHA).